The law shortens the terms of:
- approval of protocols of clinical trials of drugs for the treatment of coronavirus disease (COVID-19), vaccines or other medical immunobiological drugs for the specific prevention of coronavirus disease (COVID-19) and significant amendments thereto;
- examination of registration materials of these drugs and materials for making changes to them;
- decision-making on state registration or refusal to state registration of such medicinal products, as well as decision on making changes to such registration materials or refusal to make changes.
It is also specified that these provisions may apply only if such drugs, vaccines and immunobiologicals are registered with the competent authority of the United States of America, Great Britain, the Swiss Confederation, Japan, Australia, Canada, China, Israel, India, Mexico, Brazil. Either registered under the centralized procedure by the competent authority of the European Union, or undergo clinical trials in these countries (in one or more such countries).
Return to posts

Printable version

More posts by topic

“News”

25 February 2025 11:26
24 February 2025 10:05
05 February 2025 15:27
04 February 2025 15:10
04 February 2025 13:15
04 February 2025 09:30
30 January 2025 19:30
28 January 2025 13:20
28 January 2025 12:34
28 January 2025 12:21